Update on the role of venetoclax and rituximab in the treatment of ...

The therapeutic combination of rituximab and venetoclax is both feasible and synergistic in its effect and the combination was designated a 'break-through ...

For the treatment of mature B cell malignancies including chronic lymphocytic leukemia (CLL), the last 5 years has brought major advances in the application ...

Venetoclax Plus Rituximab Supports Immune Recovery in CLL

Researchers report on the long-term immune changes in patients with refractory or relapsed chronic lymphocytic leukemia (CLL) treated with ...

Update on the role of venetoclax and rituximab in the treatment of ...

27. Freise KJ, Jones AK, Eckert D, et al. Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory ...

Venetoclax/Rituximab Retreatment Produces Durable Responses in ...

Findings from the phase 3 MURANO trial (NCT02005471) demonstrated that treatment with the combination of venetoclax plus rituximab for a maximum ...

Combination Pirtobrutinib, Venetoclax, and Rituximab for CLL

Medically reviewed by · The combination of · Dr. · Two types of Bruton tyrosine kinase (BTK) inhibitors are used to treat chronic lymphocytic ...

Combining the Drugs Venetoclax and Rituximab as a First ... - SWOG

Previous research showed that combining venetoclax and rituximab can work well against WM that came back or didn't respond to other treatment.

Venetoclax and Rituximab Combination Maintains Survival Benefit ...

Patients with relapsed/refractory chronic lymphocytic leukemia achieved sustained progression-free survival and overall survival benefit after treatment with ...

Venetoclax-rituximab is active in patients with BTKi-exposed CLL ...

In the CLL13 trial, obinutuzumab achieved superior remission depth and duration compared with R in combination with VEN for patients with treatment-naïve CLL ...

Update on the management of relapsed/refractory chronic ... - Nature

Continuous covalent inhibitors of Bruton's tyrosine kinase (cBTKi) and fixed-duration venetoclax (Ven)-anti-CD20 monoclonal antibody (mAb) are ...

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow ...

Ma and colleagues provide a long-term follow-up of the first trial of venetoclax-rituximab treatment for relapsed chronic lymphocytic ...

Clinical Trials Using Venetoclax - NCI

It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax and rituximab may work better in treating ...

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic ...

In previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with ...

Venetoclax–Rituximab in Relapsed or Refractory Chronic ...

In total, 68 patients (35.1%) in the venetoclax–rituximab group completed the scheduled 2 years of treatment, of whom 56 had less than 3 months ...

New Drug Combination Shows Promise for CLL - NCI

The investigators did not observe any new safety concerns with the venetoclax–rituximab combination treatment. ... Sign up for email updates.

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Venetoclax–obinutuzumab with or without ibrutinib was superior to chemoimmunotherapy as first-line treatment in fit patients with CLL.

Venetoclax and Rituximab Sustains Survival Benefit After 5 Years

Treatment with the combination regimen improved progression-free survival (PFS) and overall survival (OS) over a 5-year period compared with ...

Clinical efficacy and tolerability of venetoclax plus rituximab in ...

The treatment was also effective in patients with 17p deletion [8]. In March 2018, the results of the phase III MURANO trial were published, ...

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory ...

With all patients having finished treatment, continued benefit was observed for venetoclax-rituximab compared with bendamustine-rituximab. uMRD rates were ...

MURANO: Venetoclax Plus Rituximab in Patients With Relapsed ...

In July 2022, AL was diagnosed with CLL and had been previously treated with venetoclax plus obinutuzumab upon initial diagnosis. Less than 6 ...